Latest from the BMJ

Research: Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus

Feature: Incretins and risk of neoplasia

Editorial: Incretin therapy: should adverse consequences have been anticipated?

Editorial: Helping patients make sense of the risks of taking GLP-1 agonists

Feature: Investigation: Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?

Editorial: Should we be reassured about sitagliptin?

Editorial: GLP-1 based agents and acute pancreatitis

Practice: Risk assessment of fragility fractures: summary of NICE guidance

Clinical Review: Pancreatic adenocarcinoma

Practice: Dyspepsia

See more »